B. Ojeda

3.9k citations

57 papers · 2.8k indexed · 1 hit paper · h-index 26

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis

Papers in

Reproductive Medicine 14
- Ovarian cancer diagnosis and treatment 14
Cancer Research 20
- Breast Cancer Treatment Studies 18

Co-authors: Aňa Lluch Eva Ciruelos Milvia Zambetti W. Eiermann Pinuccia Valagussa Semiglazov Vf Miguel Ángel Climent Federico Vázquez
Journals: Journal of Clinical Oncology (8 papers)British Journal of Cancer (3 papers)Gynecologic Oncology (3 papers)Annals of Oncology (3 papers)Breast Cancer Research and Treatment (3 papers)
Partner nations: Spain Italy United States

In The Last Decade

B. Ojeda

56 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort 2010 · 891 citations

Peers

Countries citing papers authored by B. Ojeda

Since Specialization

Citations

This map shows the geographic impact of B. Ojeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Ojeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Ojeda more than expected).

Fields of papers citing papers by B. Ojeda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Ojeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Ojeda. The network helps show where B. Ojeda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside B. Ojeda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B. Ojeda Line = papers co-authored together B. Ojeda links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer Gynecologic Oncology ·Amreen Husain, Yan Wang, Lars Hanker, B. Ojeda, Maarit Anttila, Enrico Breda, Peter Vuylsteke, Éric Pujade-Lauraine	2016	11
2	Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study Breast Cancer Research and Treatment ·Miguel Gil‐Gil, Meritxell Bellet, Serafín Morales, B. Ojeda, Luís Manso, Carlos Mesía, 健二冨田, Noelia Martínez-Jáñez, Mireia Melé, Antonio Llombart‐Cussac, Sònia Pernas, Patricia Villagrasa, C. Blasco, José Baselga	2015	39
3	Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer Neoplasia ·Ariadna Tibau, Laura López-Vilaró, Maitane Pérez-Olabarría, Tania Vázquez, Cristina Pons, Ignasi Gich, Carmen Alonso, B. Ojeda, Teresa Ramón y Cajal, Enrique Lerma, Agustí Barnadas, Daniel Escuín	2014	12
4	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort The Lancet Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	2014	356
5	A correlation study of thyroid nodule cytopathology and histopathology 15th International & 14th European Congress of Endocrinology ·雅俊小林, Cristina López‐Tinoco, Ed.D Sharon D. Jones Deloach, L. Larran, B. Ojeda, Inmaculada Gavilán, Keegan Downham, Marc Pélegrin, Manuel Aguilar‐Diosdado	2012	1
6	Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial) Annals of Oncology ·Eva Ciruelos, Javier Cortés, H. Cortés-Funes, José Mayordomo, Begoña Bermejo, B. Ojeda, (unknown), César A. Rodríguez, Montserrat Muñoz-Mateu, P. Gómez, Luís Manso, Raquel Andrés, Aňa Lluch, Cristina Saura, C. Mendiola, José Baselga	2009	10
7	Update in the management of ovarian and cervical carcinoma Clinical & Translational Oncology ·Andrés Poveda, Ramón Salazar, J. S. Udal, C. Mendiola, Javier Cassinello, B. Ojeda, Neşe SALİK ATA, Ana Oaknin, Jesús García‐Foncillas, María Jesús Rubio, Antonio González-Martı́n	2007	15
8	Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study Annals of Oncology ·Antonio González-Martı́n, PiergiorgioGaudenzi, Isabel Bover, María Jesús Rubio, Àngels Arcusa, Antonio Casado, B. Ojeda, Carmen Balañá, Ava B. Keating, Ana Herrero, Beatriz Pardo, Encarna Adrover, Juli Rifà, María José Godes, Ruiz Rizzo, Andrés Cervantes	2005	90
9	Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment The Breast ·José A. Martínez-Climent, Miguel Ángel Seguí, Gloria Peiró, Rafael Molina, Enrique Lerma, B. Ojeda, Qinggang Meng, Carmen Alonso	2001	26
10	Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation Bone Marrow Transplantation ·Ramón Salazar, C. Solà, Pablo Maroto, Josep Tabernero, Joan Brunet, Gerhard Heinzmann, Vicente Valentí, Sadia Lumis Gómez Ríos, B. Ojeda, Luis Mendoza, L. V. Kalinovskaja, J. Montesinos, Zuzana Jiránková	1998	61
11	Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women Breast Cancer Research and Treatment ·Miguel Navarro, Ricard Mesı́a, Orland Dı́ez, Antonio Rueda, B. Ojeda, María C. Alonso	1997	49
12	Chemotherapy And Radiotherapy In Locally Advanced Cervical Cancer Acta Oncologica ·Joan Brunet, Carmen Alonso, Marta Llanos, Adelaida La Casta, Pamela Chin, Luis Mendoza, Josep M. Badía, Wahyuddin Saputra, B. Ojeda	1995	5
13	A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer Breast Cancer Research and Treatment ·María C. Alonso, Josep Tabernero, B. Ojeda, Marta Llanos, C. Sol�, Marta Climent, Shoaib Iqbal, Ana Margarida Nogueira Vale Costa	1995	25
14	Oncogenic proteins and prognostic correlations in breast cancer. PubMed ·R. Molina, Mian Ahad Hayaud-Din, Sharif Ahmed, 蒋影明, Okan Uyar, Joshua Cutler, I. Hossain, B. Ojeda, 王玺年, Stella Hadjikyriacou	1994	1
15	Male Breast Cancer Report of a Series of 50 Cases Acta Oncologica ·Miguel Izquierdo, J. F. Brennan, Fan Li, B. Ojeda	1994	39
16	Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. Journal of Clinical Oncology ·M Estorch, Ignasi Carrió, 北川善子, L Bernà, Gustavo Torres, Carmen Alonso, B. Ojeda	1993	35
17	Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases Cancer ·Michele De Nictolis, Rodolfo Montironi, S Z Gubaev, Silvestro Carinelli, B. Ojeda, Xavier Matías‐Guiu, Jaime Prat	1992	45
18	A Prospective Study of Tumor Markers CA 125 and CA 19.9 in Patients with Epithelial Ovarian Carcinomas Tumor Biology ·Rafael Molina, B. Ojeda, Xavier Filella, Beatriz, Judith Jo, Rifqoh Zahrotul Faizah, José López López, A M Ballesta	1992	32
19	Ovarian carcinoma preceded by cerebral metastasis: Review of the literature Gynecologic Oncology ·Miguel Izquierdo, B. Ojeda, Cinta Pallarés, M. Carmen Alonso, Xavier Matías‐Guiu	1992	11
20	Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies European Journal of Nuclear Medicine and Molecular Imaging ·Ignasi Carrió, Montserrat Estorch, Lluı́s Bernà, JM Martín, Carmen Alonso, B. Ojeda, Fan Li, Antonio López–Pousa, Marino Marcich, Gustavo Torres	1991	41

About B. Ojeda

B. Ojeda is a scholar working on Reproductive Medicine, Cancer Research, Oncology, Dermatology and Obstetrics and Gynecology, having authored 57 papers that have together received 2.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (17 papers), Ovarian cancer diagnosis and treatment (14 papers), HER2/EGFR in Cancer Research (12 papers), Chemotherapy-related skin toxicity (6 papers), Endometrial and Cervical Cancer Treatments (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (5 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.9k citations), Radiology, Nuclear Medicine and Imaging (697 citations), Reproductive Medicine (255 citations) and Family Practice (48 citations). B. Ojeda has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Aňa Lluch, Eva Ciruelos, Milvia Zambetti, W. Eiermann, Pinuccia Valagussa, Semiglazov Vf, Miguel Ángel Climent, Federico Vázquez, Luca Gianni and А. А. Божок. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Gynecologic Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact